HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

KRH 1636

structure in first source

Also Known As:

KRH-1636; KRH1636

Networked: 2 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Yamamoto, Naoki: 2 articles (04/2009 - 04/2003)
2.	Yanaka, Mikiro: 2 articles (04/2009 - 04/2003)
3.	Akari, Hirofumi: 1 article (04/2009)
4.	Dewan, Md Zahidunnabi: 1 article (04/2009)
5.	Iwasaki, Yuki: 1 article (04/2009)
6.	Kumakura, Sei: 1 article (04/2009)
7.	Murakami, Tsutomu: 1 article (04/2009)
8.	Bannai, Kenji: 1 article (04/2003)
9.	Edamatsu, Takeo: 1 article (04/2003)
10.	Hirose, Kunitaka: 1 article (04/2003)

Related Diseases

1.	Infections 04/01/2003 - "Thus, KRH-1636 seems to be a promising agent for the treatment of HIV-1 infection." 04/01/2009 - "Taken together, the KRH-1636 derivatives KRH-2731 and KRH-3955 may be promising as a novel inhibitory drug for cancer metastasis as well as for human immunodeficiency virus type 1 infection."
2.	Neoplasms (Cancer) 04/01/2009 - "Taken together, the KRH-1636 derivatives KRH-2731 and KRH-3955 may be promising as a novel inhibitory drug for cancer metastasis as well as for human immunodeficiency virus type 1 infection."
3.	Neoplasm Metastasis (Metastasis) 04/01/2009 - "Taken together, the KRH-1636 derivatives KRH-2731 and KRH-3955 may be promising as a novel inhibitory drug for cancer metastasis as well as for human immunodeficiency virus type 1 infection."

Related Drugs and Biologics

1.	N,N- dipropyl- N'- (4- ((((1H- imidazol- 2- yl)methyl)((1- methyl- 1H- imidazol- 2- yl) methyl)amino)methyl)benzyl)- N'- methylbutane- 1,4- diamine